OCT-1 as a determinant of response to antileukemic treatment

Simple item page
dc.contributor.authorEngler, J.
dc.contributor.authorHughes, T.
dc.contributor.authorWhite, D.
dc.date.issued2011
dc.description.abstractDespite the excellent responses to imatinib therapy observed in patients with chronic phase chronic myeloid leukemia (CP-CML),<sup>1</sup> ∼25% of these patients demonstrate primary resistance or suboptimal response. <sup>2</sup> Inadequate inhibition of the kinase activity of BCR-ABL<sup>3</sup> due to low intracellular concentrations of imatinib achieved in target leukemic cells has been associated with suboptimal response.<sup>4</sup> The organic cation transporter 1 (OCT-1) has been identified as the major active influx pump for imatinib in CML cells,<sup>4,5</sup> and has therefore been investigated as a cause of suboptimal response in patients treated with imatinib. © 2011 ASCPT.
dc.description.statementofresponsibilityJR Engler, TP Hughes and DL White
dc.identifier.citationClinical Pharmacology and Therapeutics, 2011; 89(4):608-611
dc.identifier.doi10.1038/clpt.2011.12
dc.identifier.issn0009-9236
dc.identifier.issn1532-6535
dc.identifier.orcidHughes, T. [0000-0002-0910-3730] [0000-0002-7990-4509]
dc.identifier.orcidWhite, D. [0000-0003-4844-333X]
dc.identifier.urihttp://hdl.handle.net/2440/67140
dc.language.isoen
dc.publisherMosby Inc
dc.rights© 2011 American Society for Clinical Pharmacology and Therapeutics
dc.source.urihttps://doi.org/10.1038/clpt.2011.12
dc.subjectHumans
dc.subjectLeukemia, Myeloid, Chronic-Phase
dc.subjectBenzamides
dc.subjectPiperazines
dc.subjectPyrimidines
dc.subjectOrganic Cation Transporter 1
dc.subjectAntineoplastic Agents
dc.subjectProtein Kinase Inhibitors
dc.subjectDrug Resistance, Neoplasm
dc.subjectImatinib Mesylate
dc.titleOCT-1 as a determinant of response to antileukemic treatment
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications